Rhythm Pharmaceuticals, Inc. RYTM

What this company does

It also develops two earlier-stage investigational MC4R agonists, bivamelagon, an oral small molecule, and RM-718, designed for weekly subcutaneous administration. IMCIVREE is approved by the FDA to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to BBS, POMC, PCSK1, or LEPR deficiency, as determined by an FDA-approved test demonstrating variants in the POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance. It has achieved market access or named patient sales for IMCIVREE for BBS or POMC and LEPR deficiencies, or both, in more than 25 countries outside the United States. As of February 1, 2026, it had 414 employees, including 126 employees in 11 countries outside of North America. Rhythm Pharmaceuticals, Inc. is a Delaware corporation organized in February 2013, originally incorporated under the name Rhythm Metabolic, Inc., and, as of October 2015, under the name Rhythm Pharmaceuticals, Inc.

Written from the business description in RHYTHM PHARMACEUTICALS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.